Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Henlius and SVAX Forge Strategic Partnership in the MENAT Market 2024-11-09 00:35
Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer 2024-09-21 13:42
Henlius Trastuzumab Receives FDA Approval in the United States 2024-04-29 20:18
Henlius Releases 2023 ESG Report: Pursuing Sustainable Development with Patient-centricity 2024-04-17 20:32
Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved 2024-03-21 19:47
Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development 2024-03-04 21:28
Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development 2024-03-04 21:19
First International Shipment of HANSIZHUANG Launched 2024-01-25 21:41
First International Shipment of HANSIZHUANG 2024-01-25 20:45
HANSIZHUANG Sets Sail in Indonesia Market 2023-12-28 21:51
The NDA for New Indication of Henlius Anti-PD-1 mAb Serplulimab in Combination with Chemotherapy for the First-line Treatment of non-squamous NSCLC Accepted by the NMPA 2023-12-12 20:30
Henlius Reported Financial Results for the First Three Quarters of 2023: Total Revenue Exceeded RMB3.9 billion, Profitability Further Improved 2023-11-15 20:16
Henlius Announces NMPA Approvals of Two ADC Candidates for IND 2023-10-27 20:16
Henlius Deepens Collaboration with Intas to bring Henlius' Novel anti-PD-1 mAb Serplulimab to Europe and India 2023-10-27 19:47
Henlius Deepens Collaboration with Intas to bring Henlius' Novel anti-PD-1 mAb Serplulimab to Europe and India 2023-10-27 19:13
First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe 2023-10-25 21:15
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC 2023-09-25 07:41
Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA 2023-09-12 19:24
Henlius 2023 H1 Results: Achieved record profits and RMB2.5 billion revenues, opening a new chapter of high-quality growth 2023-08-25 19:26
HANQUYOU Marks 3rd Anniversary with Brilliant Achievements 2023-07-28 15:53
1 2 3